

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregor, et al. Confirmation No.: 4261
Serial No.: 10/541,099 Group Art Unit: 1644
Filed: 07/31/2006 Examiner: Haddad, Maher M.
Title: METHODS OF SCREENING FOR ANTI-INFLAMMATORY DRUGS AND USE THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 CFR §1.499

Dear Sir:

This is in response to the Restriction Requirement mailed June 18, 2008, which set a one-month period for response. In light of a request for two-month extension and fee therefore, enclosed herewith, response is due September 18, 2008. This response is therefore timely filed.

Claims 1-35 are pending in the application. The action requires election among nine groups of claims:

- I. **Claims 1-12**, drawn to a method of screening for small organic compounds that inhibit the interaction of GAGs with GAG specific ECAMs.
- II. **Claims 13-18**, drawn to a composition obtained from a method of screening.
- III. **Claims 19-27**, drawn to method for inhibiting cell adhesion or cell migration comprising the step of exposing a cell to a small organic compound which interacts with at least one GAG in an amount sufficient for preventing the interactions of the GAG with at least one GAG specific ECAM.
- IV. **Claims 28-29**, drawn to a method for modulating anticoagulant activity of a glycosaminoglycans comprising the step of administering a pharmaceutical composition obtained in a method of screening.
- V. **Claims 30-32**, drawn to a method for the treatment or prevention of a condition, process, or a disorder related to cell adhesion or migration comprising administering as an active ingredient a small organic compound that inhibits the interaction of at least one GAG with at least one GAG specific ECAM, wherein the process, condition or disorder is inflammatory processes.

- VI. **Claims 30 and 33**, drawn to a method as in group V, wherein the process, condition or disorder is autoimmune processes.
- VII. **Claims 30 and 34**, drawn to a method as in group V, wherein the process, condition or disorder is cancer or cancer metastasis.
- VIII. **Claims 30 and 31**, drawn to a method as in group V, wherein the process, condition or disorder is atherosclerosis.
- IX. **Claims 30-31 and 35**, drawn to a method as in group V, wherein the process, condition or disorder is bone degradation, restenosis, eczema, osteoporosis and osteoarthritis or wound healing.

Applicants hereby elect Group III (Claims 19-27) without traverse for further prosecution in this application. In reply to the species election requirement, Applicants elect heparan sulfate (HS-GAG) as the specific GAG species and L-selectin as the specific GAG specific ECAM species.

Respectfully submitted,



Kellie S. Fredericks
Agent for Applicants
Registration No. 61,998

Dated: September 12, 2008

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579